Company intelligence / Profile preview

Zytoprotec

Ownership: Private
Development stage: Phase 2

Overview

In Phase II clinical trials, their lead product PDprotec® met both primary endpoints and showed promising results with no patients developing peritonitis while using the product, compared to four patients who developed peritonitis with standard care[6].

Therapeutic areas: Nephrology
Modalities: Cytoprotective compounds
Industry: Biotech

Drug pipeline

1 asset

PD-protec

Unknown

Beyond the preview

Go deeper on Zytoprotec.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zytoprotec.

Explore the full profile